Preconditioning DCs with immune adjuvants Flt3L and TLR3 has been shown in studies to successfully increase DC aggregation, tumor antigen-specific CD8+ T cell proliferation, and antitumor immunological impact [46, 47]. This evidence concerns the gene CD8A and neoplasm.